Ayaki Masahiko, Iwasawa Atsuo, Niwano Yoshimi
Department of Ophthalmology, Mita Hospital, International University of Health and Welfare, Tokyo Institute of Technology, Japan.
Biocontrol Sci. 2012;17(3):121-8. doi: 10.4265/bio.17.121.
We evaluated the in vitro cytotoxicity of benzalkonium chloride (BAK)-containing antiglaucoma eyedrops. We prepared cell cultures of SIRC, BCE C/D-1b, RC-1, and Chang conjunctiva. The viability of cell cultures was determined using the MTT and neutral red assays. The cell viability score (CVS) was used to compare the toxicity of test solutions. %CVS50 and %CVS40/80 of each eyedrop solution were 71 and 26 for Lumigan(®) (0.002% bimatoprost with 0.005% BAK), 100 and 99 for Tapros(®) (0.0015% tafluprost, a new formula from 2010 with 0.001% BAK), 39 and -29 for 2% Trusopt(®) (2% dorzolamide with 0.0075% BAK), 28 and -43 for Xalacom(®) (latanoprost/0.5% timolol with 0.02% BAK), 88 and 66 for DuoTrav(®) (travoprost/0.5% timolol with no BAK), 36 and -35 for Cosopt(®) (2% dorzolamide/0.5% timolol with 0.0075% BAK) and 53 and -1 for Combigan(®) (0.15% brimonidin/0.5% timolol with 0.005% BAK). Only Xalacom(®) and Tapros(®) did not show an apparent decrease in %CVS as compared to the corresponding concentration of BAK. In conclusion, the cytotoxicity of tested eyedrops was dependent on BAK. Only the eyedrops containing latanoprost or tafluprost showed a reduction in the cytotoxicity of BAK.
我们评估了含苯扎氯铵（BAK）的抗青光眼滴眼液的体外细胞毒性。我们制备了SIRC、BCE C/D - 1b、RC - 1和张氏结膜的细胞培养物。使用MTT和中性红试验测定细胞培养物的活力。细胞活力评分（CVS）用于比较测试溶液的毒性。卢美根（Lumigan®）（0.002%比马前列素与0.005% BAK）的%CVS50和%CVS40/80分别为71和26，他氟前列素滴眼液（Tapros®）（0.0015%他氟前列素，2010年新配方，含0.001% BAK）为100和99，2%派立明（Trusopt®）（2%多佐胺与0.0075% BAK）为39和 - 29，适利达（Xalacom®）（拉坦前列素/0.5%噻吗洛尔与0.02% BAK）为28和 - 43，复美达（DuoTrav®）（曲伏前列素/0.5%噻吗洛尔，不含BAK）为88和66，可速普（Cosopt®）（2%多佐胺/0.5%噻吗洛尔与0.0075% BAK）为36和 - 35，复方托吡卡胺（Combigan®）（0.15%溴莫尼定/0.5%噻吗洛尔与0.005% BAK）为53和 - 1。与相应浓度的BAK相比，只有适利达（Xalacom®）和他氟前列素滴眼液（Tapros®）的%CVS没有明显下降。总之，受试滴眼液的细胞毒性取决于BAK。只有含拉坦前列素或他氟前列素的滴眼液显示出BAK细胞毒性的降低。
